Invention Description
Chronic and slow-healing wounds, particularly in diabetic and obese patients, pose a significant global, medical, and economic burden due to poor healing outcomes and limited effective treatments. Post-operative complications such as intestinal adhesions further complicate recovery and emphasize the need for targeted wound therapies.
Researchers at Arizona State University have developed a novel class of bioactive, histamine- or histidine-conjugated hyaluronic acid-based polymers that activate innate immunity to accelerate tissue repair, prevent adhesions, and improve wound healing outcomes. These polymers serve as wound dressings or vaccine adjuvants to enhance immune cell recruitment and wound closure. They have been demonstrated through in vitro and in vivo studies to show enhanced immune cell recruitment and faster wound closure in animal models. This innovation delivers the right bioactives at precise healing stages, promoting multifaceted tissue regeneration and offering a powerful new option in regenerative medicine.
By leveraging innate immunity activation, this technology represents a new class of therapeutic materials for adhesion prevention and regenerative medicine.
Potential Applications
- Advanced wound care products for chronic and acute injuries
- Post-surgical adhesion prevention in abdominal and intestinal procedures
- Vaccine adjuvant platforms to improve immunogenic response
- Biomaterial-based regenerative medicine treatments
Benefits and Advantages
- Effectively activates innate immune responses to promote tissue repair
- Enhances wound closure and accelerates healing processes
- Utilizes well-characterized biocompatible polymer backbone (hyaluronic acid)
- Functions as both wound dressing and vaccine adjuvant
- Superior bioactive delivery compared to existing wound care products
- Supported by in vitro and in vivo validation studies
For more information about this opportunity, please see